ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DPH Dechra Pharmaceuticals Plc

3,866.00
0.00 (0.00%)
20 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Dechra Pharmaceuticals Plc LSE:DPH London Ordinary Share GB0009633180 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3,866.00 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

NATIXIS: Form 8.3 - Dechra Pharmaceuticals plc

16/01/2024 1:31pm

UK Regulatory


Dechra Pharmaceuticals (LSE:DPH)
Historical Stock Chart


From Dec 2023 to Dec 2024

Click Here for more Dechra Pharmaceuticals Charts.
TIDMDPH 
 
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

 

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 
(a) Full name of discloser:                         NATIXIS SA 
(b) Owner or controller of interests and short 
positions disclosed, if different from 1(a): The 
naming of nominee or vehicle companies is 
insufficient. For a trust, the trustee(s), settlor 
and beneficiaries must be named. 
(c) Name of offeror/offeree in relation to whose    Dechra Pharmaceuticals plc 
relevant securities this form relates: Use a 
separate form for each offeror/offeree 
(d) If an exempt fund manager connected with an 
offeror/offeree, state this and specify identity 
of offeror/offeree: 
(e) Date position held/dealing undertaken: For an   15 January 2024 
opening position disclosure, state the latest 
practicable date prior to the disclosure 
(f) In addition to the company in 1(c) above, is    NO 
the discloser making disclosures in respect of any 
other party to the offer? If it is a cash offer or 
possible cash offer, state "N/A" 
 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 
Class of relevant security:                 1p ordinary 
                                            Interests        Short positions 
                                            Number     %     Number       % 
(1) Relevant securities owned and/or 
 controlled:                                1 449 438  1,27  1 814        0,00 
(2) Cash-settled derivatives:               1 814      0,00  1 449 438    1,27 
(3) Stock-settled derivatives (including 
options) and agreements to purchase/sell: 
 
 TOTAL:                                     1 451 252  1,27  1 451 252    1,27 
 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 
Class of relevant security in relation to which subscription right exists: 
Details, including nature of the rights concerned and relevant percentages: 
 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 
Class of relevant          Purchase/sale  Number of securities  Price per unit 
security 
1p ordinary                Sale           61 400                GBX 3 866.00 
 

(b) Cash-settled derivative transactions

 
Class of       Product        Nature of dealing    Number of     Price per 
relevant       description    e.g.                 reference     unit 
security       e.g. CFD       opening/closing a    securities 
                              long/short 
                              position, 
                              increasing/reducing 
                              a long/short 
                              position 
1p ordinary    Futures        Decreasing a short   61 400        GBX 3 866.00 
                              position 
 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 
Class of  Product      Writing,     Number of   Exercise  Type e.g.  Expiry  Option 
relevant  description  purchasing,  securities  price     American,  date    money 
security  e.g. call    selling,     to which    per       European           paid/ 
          option       varying      option      unit      etc.               received 
                       etc.         relates                                  per 
                                                                             unit 
 
 

(ii) Exercise

 
Class of        Product         Exercising/     Number of       Exercise price 
relevant        description     exercised       securities      per unit 
security        e.g. call       against 
                option 
 
 

(d) Other dealings (including subscribing for new securities)

 
Class of relevant       Nature of dealing      Details  Price per unit (if 
security                e.g. subscription,              applicable) 
                        conversion 
 
 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 
Details of any indemnity or option arrangement, or any agreement or 
understanding, formal or informal, relating to relevant securities which may 
be an inducement to deal or refrain from dealing entered into by the person 
making the disclosure and any party to the offer or any person acting in 
concert with a party to the offer: Irrevocable commitments and letters of 
intent should not be included. If there are no such agreements, arrangements 
or understandings, state "none" 
 
 NONE 
 

(b) Agreements, arrangements or understandings relating to options or derivatives

 
Details of any agreement, arrangement or understanding, formal or informal, 
between the person making the disclosure and any other person relating to: (i) 
the voting rights of any relevant securities under any option; or (ii) the 
voting rights or future acquisition or disposal of any relevant securities to 
which any derivative is referenced: If there are no such agreements, 
arrangements or understandings, state "none" 
 
 NONE 
 

(c) Attachments

 
Is a Supplemental Form 8 (Open Positions) attached?  NO 
 
 
Date of disclosure:   16 January 2024 
Contact name:         Florence de Queylar 
Telephone number*:    +33 1 58 19 40 93 
 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240116105834/en/

 
    CONTACT: 

NATIXIS

 
    SOURCE: NATIXIS 
Copyright Business Wire 2024 
 

(END) Dow Jones Newswires

January 16, 2024 08:31 ET (13:31 GMT)

1 Year Dechra Pharmaceuticals Chart

1 Year Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

1 Month Dechra Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock